Free tool
FAERS Monitor: Zylet
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050804 or its brand name (Zylet, Loteprednol Etabonate, Tobramycin). Reports on generic versions are filed under their own applications.
Reports
400
Serious
116
29% of reports
Hospitalization
40
Death reported
9
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain49
- ocular hyperaemia48
- eye irritation47
- drug ineffective41
- vision blurred31
- headache30
- lacrimation increased28
- eye pruritus21
- chronic kidney disease20
- eye swelling19
- condition aggravated18
- drug hypersensitivity18
- hypersensitivity18
- visual impairment16
- renal failure13
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 24 |
| 2008 | 18 |
| 2009 | 4 |
| 2010 | 26 |
| 2011 | 24 |
| 2012 | 20 |
| 2013 | 7 |
| 2014 | 8 |
| 2015 | 20 |
| 2016 | 24 |
| 2017 | 32 |
| 2018 | 39 |
| 2019 | 56 |
| 2020 | 22 |
| 2021 | 22 |
| 2022 | 26 |
| 2023 | 9 |
| 2024 | 6 |
| 2025 | 10 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,759 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ocular hyperaemiaSignal | 48 | 53.2 | 40.8 | 2,411 |
| lacrimation increasedSignal | 28 | 48.8 | 34.1 | 1,263 |
| eye painSignal | 49 | 45.7 | 35.2 | 2,102 |
| eye irritationSignal | 47 | 43.0 | 32.8 | 1,889 |
| eye pruritusSignal | 21 | 32.9 | 21.7 | 618 |
| eye swellingSignal | 19 | 26.9 | 17.3 | 448 |
| chronic kidney diseaseSignal | 20 | 13.8 | 9.0 | 226 |
| vision blurredSignal | 31 | 11.9 | 8.5 | 300 |
| visual impairmentSignal | 16 | 6.8 | 4.2 | 74 |
| renal failureSignal | 13 | 5.1 | 3.0 | 40 |
| hypersensitivitySignal | 18 | 5.1 | 3.2 | 56 |
| drug hypersensitivitySignal | 18 | 4.9 | 3.1 | 52 |
| condition aggravatedSignal | 18 | 3.1 | 2.0 | 24 |
| headacheSignal | 30 | 2.5 | 1.8 | 27 |
| drug ineffective | 41 | 1.6 | 1.2 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.